Company news
Vivani Medical, Inc. (NASDAQ:VANI) news
Vivani Medical, Inc. news releases on 6ix. Latest, Sep 3, 2026: Vivani Medical Announces Participation in Upcoming Investor Conferences
Press releases & updates
Vivani Medical Announces Participation in Upcoming Investor Conferences
September 3, 2026
Vivani Medical : Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
August 6, 2026
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
July 14, 2026
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
July 7, 2026
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
July 1, 2026
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
June 26, 2026
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
June 25, 2026
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
June 22, 2026
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026
May 28, 2026
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
May 13, 2026
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 25, 2026
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
January 29, 2026
Vivani Medical, Inc. Announces Closing of Common Stock Offering
January 27, 2026
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
January 24, 2026
Vivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026
January 22, 2026
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
November 13, 2025
Vivani Medical to Present at the ThinkEquity Conference on October 30, 2025
October 22, 2025
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
October 3, 2025
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
September 24, 2025
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
September 17, 2025
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
September 4, 2025
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
August 20, 2025
Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
August 13, 2025
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
August 5, 2025
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
June 11, 2025
Vivani Medical to Present at the 2025 BIO International Convention
June 10, 2025
Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
May 29, 2025
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
May 13, 2025
Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
May 7, 2025
Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
April 16, 2025
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
April 15, 2025
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 31, 2025
Vivani Medical Announces $8.25M Private Placement Equity Financing
March 27, 2025
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
March 26, 2025
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
March 24, 2025
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
March 13, 2025
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
March 12, 2025
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
December 18, 2024
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
December 3, 2024
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
November 12, 2024
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
October 21, 2024
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
September 25, 2024
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
September 22, 2024
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
September 3, 2024
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
August 12, 2024
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
July 10, 2024
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
June 12, 2024